JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.
JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.